Author: admin

The Life of Jesus: History’s Great Love Story by Rev Dr Geoffrey Waugh Offers Inspired Insight into the Radical Life and Love of Jesus

For centuries, Jesus Christ has transformed and continues to transform societies, impacting the lives of billions of people around the world. In The Life of Jesus: History’s Great Love Story, author Geoffrey Waugh offers fresh insight into the radical life and love of Jesus.

Rev Dr Geoffrey Waugh is the founding editor of the Renewal Journal (renewaljournal.com) and the author of many books on ministry and mission including The Life of Jesus, Flashpoints of Revival, Living in the Spirit, God’s Surprises, Journey into Ministry and Mission, and more.

After completing theological college, Geoff taught on renewal and revival at Bible College, Trinity Theological College, and Christian Heritage College. He has enjoyed cross-cultural mission and taught on revival to church leaders in Africa, Nepal, India, Sri Lanka, Myanmar, Thailand, the Philippines, China, and the South Pacific nations of Papua New Guinea, the Solomon Islands, Vanuatu, and Fiji. He has also led many teams on service and mission in Europe, Africa, Asia, and the South Pacific.

This one-on-one interview shares Geoffrey Waugh’s background and experience in writing The Life of Jesus: History’s Great Love Story.

Tell us about The Life of Jesus: History’s Great Love Story.

The Life of Jesus provides a brief overview of history’s great love story.

It gives a summary of the birth and boyhood of Jesus and describes his ministry through three Passover Festivals.

It includes a detailed chronology of Jesus’ life and ministry, and examines why such a popular, loving, and compassionate young leader would encounter such intense hostility and opposition, leading to his crucifixion.

Offering fresh insights, The Life of Jesus points you to the great good news of who Jesus is and what he did.

What inspired you to write The Life of Jesus: History’s Great Love Story?

The life of Jesus is a vast topic, with millions of books written about it. I wanted to write a summary overview that people of all ages could read and understand.

In the book, I explore why such a young, radical leader who loved all people of all races was executed, and why we date our calendars and diaries from the time of his birth. I hope my contribution provides a helpful overview.

How did your background and experience influence your writing?

I have always believed in Jesus. Even as a small boy, I loved to hear and read stories about him because he was so unique and different. He always did what was good. He healed the sick, fed the hungry, set people free from addictions and evil, performed miracles, and even raised dead people. Huge crowds of people followed him and wanted him to be their king. Now, billions of people follow him, captivated and transformed by his love.

Through my experience teaching about Jesus in colleges in five countries, and speaking about Him through invitations from community groups in twenty countries, my passion and dedication has grown. Through the book, I offer fresh insights into his life and love.

What is one message you would like readers to remember?

Jesus’ unique and wonderful life, his brutal death for us, and his powerful resurrection, all reveal his and God’s eternal love for us all. That love, powerfully shown on the cross, has transformed billions of lives, restoring believers to an intimate and eternal relationship with God and with others.

Purchasing the Book

The Life of Jesus: History’s Great Love Story has received positive reviews from well-known literary organizations, experts and reviewers around the world. Rev Dr Tony Cupit, Former Director of the Baptist World Alliance writes, “Geoff has used Scripture as his main source and has been faithful to both the divinity and humanity of Jesus as expressed in the Gospels. His use of chronology for headings and the many subheadings makes the book simpler to absorb, even for an enquirer or new believer…I warmly commend this book.” In addition, Rev Dr John Olley writes, “A most helpful telling of the life of Jesus…anyone using this book will be enriched.”

Powerful and informative, The Life of Jesus: History’s Great Love Story, is available for sale on Amazon, Barnes & Noble, Kobo, Google Play, and other online bookstores. Readers who are looking for a deeper understanding of the life and love of Jesus are encouraged to purchase their copy today: https://www.amazon.com/Life-Jesus-Historys-Great-Story/dp/1664268154

Connect with Geoffrey Waugh

https://renewaljournal.com/2022/05/08/the-life-of-jesus/

https://www.facebook.com/HistorysGreatLoveStory

https://www.westbowpress.com/en/bookstore/bookdetails/841002-the-life-of-jesus

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Life of Jesus: History\’s Great Love Story by Rev Dr Geoffrey Waugh Offers Inspired Insight into the Radical Life and Love of Jesus

Transforming Perception, Elevating Care – Dr. Jaqlyn’s Tinaro Redefines Online Presence for a Healthier Tomorrow.

Dr. Jaqlyn’s Tinaro, a distinguished healthcare professional, proudly announces the launch of its revamped brand identity and website. This strategic move comes as part of a proactive approach to counter negative online sentiments and enhance the overall online presence.

Revolutionizing Online Presence

In an era where digital reputation is paramount, Dr. Jaqlyn’s Tinaro recognizes the importance of a positive and influential online image. The newly launched website, coupled with a revamped brand identity, is designed to address and counteract any negative reviews or information present on search engine result pages (SERPs).

Navigating Reputation Management Challenges

Dr. Jaqlyn’s Tinaro has taken a proactive stance in managing its online reputation. By investing in a comprehensive branding strategy and an upgraded website, the healthcare professional aims to present an accurate and positive representation to online audiences. The website serves as a hub for accurate and up-to-date information about Dr. Jaqlyn’s Tinaro’s values, and commitment to educating the public in regards to naturopathy and functional medicine. patient care.

Key Features of the Redesigned Website:

The website is designed with user experience in mind, offering a streamlined and user-friendly interface. Visitors can easily navigate through the site to find relevant information about Dr. Jaqlyn’s Tinaro’s expertise and products. 

The site provides comprehensive details about education on naturopathy, spirituality and animal welfare.

Dr. Jaqlyn’s Tinaro recognizes the importance of education and transparency. The website features a blog and resources section to share valuable insights, tips, and industry updates, reinforcing the healthcare professional’s commitment to patient education.

To encourage communication and engagement, the website incorporates interactive contact options, making it easy for visitors to connect with Dr. Jaqlyn’s Tinaro for inquiries, or feedback.

Navigating Negative SERP Rankings

Acknowledging the challenges posed by negative search engine results, Dr. Jaqlyn’s Tinaro has implemented a targeted strategy to enhance its online reputation. The newly launched website is optimized to counteract negative information and present a more accurate and positive portrayal of Dr. Jaqlyn’s Tinaro’s professional achievements and commitment to education on Naturopathy and functional medicine.

Dr. Jaqlyn’s Tinaro on the Rebranding Effort

“Recognizing the significance of our online presence, we have undertaken this strategic rebranding initiative to ensure that our digital identity accurately reflects our values and commitment to healthcare excellence. Our revamped website not only provides a user-friendly experience but also serves as a tool to counteract any misleading information online,” says one of the clients’, the spokesperson for Dr. Jaqlyn’s Tinaro.

About Dr. Jaqlyn’s Tinaro

Dr. Jaqlyn’s Tinaro is a reputable Naturopath dedicated to providing high-quality education and insight on functional medicine, spirituality and holistic animal care. Dr. Jaqlyn’s Tinaro has taken proactive steps to address any challenges posed by negative online sentiments. Driven by a dedication to counteract negative sentiments on SERPs, Dr. Jaqlyn’s Tinaro strives to provide accurate information and foster trust. The newly launched website, https://www.drjaqlyn.com, reflects the commitment to transparency and education. 

Media Contact
Company Name: Dr. Jaqlyn’s Tinaro
Contact Person: Media Relation
Email: Send Email
Country: United States
Website: https://www.drjaqlyn.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Transforming Perception, Elevating Care – Dr. Jaqlyn\’s Tinaro Redefines Online Presence for a Healthier Tomorrow.

Make the Most of Winter Vacation with Colorado Resort Transportation by Epic Limo Services Inc.

To make the most of a trip, it’s essential to have reliable and convenient transportation. That’s where Epic Limo Services Inc comes in.

Winter vacation in Colorado is a magical time filled with snowy mountains, cozy cabins, and thrilling outdoor activities. To make the most of a trip, it’s essential to have reliable and convenient transportation. That’s where Epic Limo Services Inc comes in.

Epic Limo Services Inc offers top-notch transportation services specifically tailored to Colorado resorts. Whether you’re staying in Aspen, Vail, Breckenridge, or any other popular destination, their experienced drivers will ensure you reach your resort safely and on time.

Here’s how Epic Limo Services Inc can enhance your winter vacation:

1. Comfortable and Luxurious Vehicles: Traveling in style is always a plus, and Epic Limo Services Inc delivers just that. Their fleet consists of luxurious vehicles that are well-maintained and equipped with modern amenities, such as leather seats, climate control, and entertainment systems. Sit back, relax, and enjoy a comfortable ride to the resort.

2. Experienced and Professional Drivers: The drivers at Epic Limo Services Inc are not only experienced but also knowledgeable about the best routes to your destination. They are familiar with the road conditions during winter and know how to navigate through snow-covered mountain roads safely. You can trust them to provide a smooth and stress-free journey.

3. Safety First: Safety is a top priority for Epic Limo Services Inc. Their vehicles are equipped with advanced safety features, including anti-lock brakes and traction control, to ensure a secure ride. Additionally, their drivers undergo thorough background checks and regular training to guarantee your safety throughout the journey.

4. Convenience and Flexibility: Epic Limo Services Inc understands that vacation schedules can change, especially during the winter season when weather conditions can be unpredictable. That’s why they offer flexible transportation options. Whether you need a one-way trip, round-trip, or multiple stops along the way, they can accommodate your needs and adjust the schedule accordingly.

5. Local Expertise: Colorado is known for its stunning ski resorts, but there’s so much more to explore. Epic Limo Services Inc’s drivers have extensive knowledge of the area and can provide valuable recommendations on nearby attractions, restaurants, and activities. They can help you make the most of your vacation by suggesting hidden gems and local favorites.

Don’t let transportation woes dampen a winter vacation in Colorado. Choose Epic Limo Services Inc for reliable, comfortable, and convenient resort transportation. With their expertise and dedication to customer satisfaction, they will ensure that the trip is nothing short of epic.

Media Contact
Company Name: Epic Limo Services Inc.
Email: Send Email
Phone: (970) 390-0883
Address:1300 N Frontage Rd W #6135
City: Vail
State: CO
Country: United States
Website: https://epiclimovail.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Make the Most of Winter Vacation with Colorado Resort Transportation by Epic Limo Services Inc.

Cyclin-Dependent Kinase Inhibitor Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cyclin-Dependent Kinase Inhibitor pipeline constitutes 45+ key companies continuously working towards developing 52+ Cyclin-Dependent Kinase Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Cyclin-Dependent Kinase Inhibitor Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Cyclin-Dependent Kinase Inhibitor Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cyclin-Dependent Kinase Inhibitor Market.

 

Some of the key takeaways from the Cyclin-Dependent Kinase Inhibitor Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Cyclin-Dependent Kinase Inhibitor treatment therapies with a considerable amount of success over the years. 
  • Cyclin-Dependent Kinase Inhibitor companies working in the treatment market are Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others, are developing therapies for the Cyclin-Dependent Kinase Inhibitor treatment 
  • Emerging Cyclin-Dependent Kinase Inhibitor therapies in the different phases of clinical trials are- SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others are expected to have a significant impact on the Cyclin-Dependent Kinase Inhibitor market in the coming years.   
  • In April 2023, Insilico Medicine declared the successful identification of a powerful, specific, and orally absorbable small molecule CDK8 inhibitor for combating cancer. This breakthrough was achieved utilizing a structure-based generative chemistry method facilitated by the Chemistry42 multi-modal generative reinforcement learning platform. The research findings were published in the Journal of Medicinal Chemistry by the American Chemical Society, renowned for its contributions to medicinal chemistry.
  • In April 2023, Sumitomo Pharma Oncology, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designation to TP-1287, an experimental oral inhibitor targeting CDK9, for addressing Ewing sarcoma. TP-1287 serves as an investigative oral phosphate prodrug developed from the CDK9 inhibitor alvocidib.
  • In March 2023, Prelude Therapeutics Incorporated (Prelude) revealed a collaboration in clinical trials with BeiGene, aiming to explore their investigational CDK9 inhibitor, PRT2527, in combination with BeiGene’s BTK inhibitor, zanubrutinib, for hematologic malignancies. According to the agreement, BeiGene will supply zanubrutinib to Prelude, granting Prelude complete global control over the operational, developmental, and commercial aspects associated with PRT2527.
  • In September 2022, Syros Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) has awarded orphan drug designation (ODD) to SY-5609, intended for addressing pancreatic cancer. SY-5609 is an orally administered, highly selective, and potent inhibitor of cyclin-dependent kinase 7 (CDK7). Presently, it is under assessment in conjunction with chemotherapy as a potential treatment for patients confronting relapsed metastatic pancreatic cancer.
  • In September 2022, Qurient Co. Ltd. revealed its partnership with MSD (Merck & Co., Inc., Rahway, NJ., USA) through a clinical collaboration agreement concerning the examination of Q901, a specific CDK7 inhibitor, in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab). As part of this agreement, Qurient will conduct a phase 1/2 study in the United States aimed at assessing the safety and effectiveness of Q901 along with KEYTRUDA for treating specific advanced solid tumors.
  • In March 2022, Kirilys Therapeutics, Inc., disclosed the closure of a seed funding round primarily overseen by Lightspeed Venture Partners. The company acquired the license for its primary compound, KRLS-017, from Ube Industries, Ltd., a leading Japanese chemical manufacturer. Additionally, Kirilys finalized a partnership pact with D2G Oncology, Inc., renowned for utilizing genetically defined animal tumor models to decipher connections between cancer genotypes and drug effectiveness. This funding round empowered Kirilys to complete all essential tasks until the IND filing of KRLS-017, including preliminary groundwork for the Phase 1 clinical development program.

 

Cyclin-Dependent Kinase Inhibitor Overview

The Cyclin-dependent kinase inhibitor protein, referred to as CKIs, CDIs, or CDKIs, acts as a suppressor of tumor growth by impeding the activity of cycling-dependent kinase (CDK) and Cyclin enzymes when the cell encounters unfavorable conditions. These proteins are involved in halting the cell cycle progression, particularly at the G1 phase, thereby preventing further advancement in unfavorable conditions.

 

Get a Free Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/cyclin-dependent-kinase-inhibitor-pipeline-insight

 

Emerging Cyclin-Dependent Kinase Inhibitor Drugs Under Different Phases of Clinical Development Include:

  • SY-5609: Syros Pharmaceutical
  • XL 102: Exelixis
  • PRT3645: Prelude Therapeutics
  • BLU 222: Blueprint Medicines
  • Enitociclib: Vincerx Pharma
  • SHR-6390: Jiangsu Hengrui Medicine Co.
  • Milciclib: Tiziana Life Sciences
  • XZP 3287: Xuanzhu Biopharmaceutical
  • Abemaciclib: Eli Lilly and Company
  • GB491 (lerociclib): Genor Pharma
  • Auceliciclib: Aucentra Therapeutics/University of South Australia
  • AU2-94: Aucentra Therapeutics

 

Cyclin-Dependent Kinase Inhibitor Route of Administration

Cyclin-Dependent Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Cyclin-Dependent Kinase Inhibitor Molecule Type

Cyclin-Dependent Kinase Inhibitor Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy 

 

Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics Assessment

  • Cyclin-Dependent Kinase Inhibitor Assessment by Product Type
  • Cyclin-Dependent Kinase Inhibitor By Stage and Product Type
  • Cyclin-Dependent Kinase Inhibitor Assessment by Route of Administration
  • Cyclin-Dependent Kinase Inhibitor By Stage and Route of Administration
  • Cyclin-Dependent Kinase Inhibitor Assessment by Molecule Type
  • Cyclin-Dependent Kinase Inhibitor by Stage and Molecule Type

 

DelveInsight’s Cyclin-Dependent Kinase Inhibitor Report covers around 52+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Cyclin-Dependent Kinase Inhibitor product details are provided in the report. Download the Cyclin-Dependent Kinase Inhibitor pipeline report to learn more about the emerging Cyclin-Dependent Kinase Inhibitor therapies

 

Some of the key companies in the Cyclin-Dependent Kinase Inhibitor Therapeutics Market include:

Key companies developing therapies for Cyclin-Dependent Kinase Inhibitor are – MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer, Novartis Pharmaceuticals, TYK Medicine, BioTheryX, Concarlo Therapeutics, Eli Lilly and Company, Kronos Bio, Syros Pharmaceuticals, Jiangsu Hengrui Medicine, Aucentra Therapeutics, Exelixis, -Qurient Co. Ltd., OnQuality Pharmaceuticals, Incyte Corporation, G1 Therapeutics, Blueprint Medicines, Cyclacel Pharmaceuticals, Nerviano Medical Sciences, Vichem Chemie, Prelude Therapeutics, Kirilys Therapeutics, Sumitomo Pharma Oncology, Insilico Medicine, Cedilla Therapeutics, Relay Therapeutics, and others.

 

Cyclin-Dependent Kinase Inhibitor Pipeline Analysis:

The Cyclin-Dependent Kinase Inhibitor pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Cyclin-Dependent Kinase Inhibitor with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cyclin-Dependent Kinase Inhibitor Treatment.
  • Cyclin-Dependent Kinase Inhibitor key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Cyclin-Dependent Kinase Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cyclin-Dependent Kinase Inhibitor market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Cyclin-Dependent Kinase Inhibitor drugs and therapies

 

Cyclin-Dependent Kinase Inhibitor Pipeline Market Drivers

  • Rising prevalence of Cancer, increasing research and development projects for the launch of new drugs are some of the important factors that are fueling the Cyclin-Dependent Kinase Inhibitor Market.

 

Cyclin-Dependent Kinase Inhibitor Pipeline Market Barriers

  • However, high cost associated with the treatment, side-effects associated with the Cyclin-Dependent Kinase Inhibitor immunotherapy and other factors are creating obstacles in the Cyclin-Dependent Kinase Inhibitor Market growth.

 

Scope of Cyclin-Dependent Kinase Inhibitor Pipeline Drug Insight    

  • Coverage: Global
  • Key Cyclin-Dependent Kinase Inhibitor Companies: Syros Pharmaceuticals, Exelixis, Prelude Therapeutics Blueprint Medicines, Vincerx Pharma, Jiangsu Hengrui Medicine Co., Tiziana Life Sciences, Xuanzhu Biopharmaceutical, Eli Lilly and Company, Genor Pharma, Aucentra Therapeutics, and others
  • Key Cyclin-Dependent Kinase Inhibitor Therapies: SY-5609, XL 102, PRT3645, BLU 222, Enitociclib, SHR-6390, Milciclib, XZP 3287, Abemaciclib, GB491 (lerociclib), Auceliciclib, AU2-94, and others
  • Cyclin-Dependent Kinase Inhibitor Therapeutic Assessment: Cyclin-Dependent Kinase Inhibitor current marketed and Cyclin-Dependent Kinase Inhibitor emerging therapies
  • Cyclin-Dependent Kinase Inhibitor Market Dynamics: Cyclin-Dependent Kinase Inhibitor market drivers and Cyclin-Dependent Kinase Inhibitor market barriers 

 

Request for Sample PDF Report for Cyclin-Dependent Kinase Inhibitor Pipeline Assessment and clinical trials

 

Table of Contents

1. Cyclin-Dependent Kinase Inhibitor Report Introduction

2. Cyclin-Dependent Kinase Inhibitor Executive Summary

3. Cyclin-Dependent Kinase Inhibitor Overview

4. Cyclin-Dependent Kinase Inhibitor- Analytical Perspective In-depth Commercial Assessment

5. Cyclin-Dependent Kinase Inhibitor Pipeline Therapeutics

6. Cyclin-Dependent Kinase Inhibitor Late Stage Products (Phase II/III)

7. Cyclin-Dependent Kinase Inhibitor Mid Stage Products (Phase II)

8. Cyclin-Dependent Kinase Inhibitor Early Stage Products (Phase I)

9. Cyclin-Dependent Kinase Inhibitor Preclinical Stage Products

10. Cyclin-Dependent Kinase Inhibitor Therapeutics Assessment

11. Cyclin-Dependent Kinase Inhibitor Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Cyclin-Dependent Kinase Inhibitor Key Companies

14. Cyclin-Dependent Kinase Inhibitor Key Products

15. Cyclin-Dependent Kinase Inhibitor Unmet Needs

16 . Cyclin-Dependent Kinase Inhibitor Market Drivers and Barriers

17. Cyclin-Dependent Kinase Inhibitor Future Perspectives and Conclusion

18. Cyclin-Dependent Kinase Inhibitor Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cyclin-Dependent Kinase Inhibitor Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | MEI Pharma, Vincerx Pharma, Chordia Therapeutics, Pfizer

Halmahera Resources Works on Building a Stronger Line of Security

“halmaheraresources.com”
Safety production is a major concern and the company is committed to increasing employees’ safety awareness

Halmahera Resources, ISIN: IDA003250200, a leading low-cost producer of nickel that generates sustainable prosperity for our employees, investors, and the communities in which it operates, is pleased to announce that the company engages in actions to support production safety, and pays close attention to study and training.

Numerous business KPIs (Key Performance Indicators) are significantly impacted by worker safety. In other words, safer workplaces benefit from fewer accidents, which reduces the cost of occupational health care, improves employee satisfaction and retention, reduces employee downtime, and reduces the need for retraining.

“Halmahera Resources has established well-organized workplace safety policies. We recognize that missing prioritizing workplace safety can have negative effects on employees’ health, safety, and wellness and that having a solid plan in place can help prevent these problems. We are continuously taking measures to make sure we offer our employees a safe workplace”, said Hashim T. Panigoro, Chairman and CEO at Halmahera Resources.

An important step followed by the company is the creation of safety policies and procedures after listing all potential workplace dangers. Employees can consult the safety guidelines at Halmahera Resources whenever they are concerned.

Halmahera Resources keeps working on creating a workplace that is focused on the employees, reinforcing a great employee experience, and promoting a culture of safety. In that instance, it is imperative that all of the staff members — including supervisors and leaders—are coordinated and on the same page. The company does not overlook the significance of open and transparent workplace communications in this situation.

Safety communications are now being implemented by Halmahera Resources as a fundamental corporate value. This emphasis on creating a workplace that prioritizes safety enhances both employee satisfaction and financial performance.

About Halmahera Resources

HalmaheraResources.com takes pride in being a leading low-cost producer of nickel that generates sustainable prosperity for our employees, investors, and the communities in which it operates. Its primary objective is producing high-grade nickel at its Halmahera Project in South Halmahera Regency, North Maluku Province, Indonesia. As a byproduct of nickel mining, the company also produces cobalt, rhodium, selenium, tellurium, sulphur, and other products. The Halmahera Resources’ core operations are prospecting, exploration, mining, concentration, and processing of minerals along with the production, marketing, and sales of non-ferrous metals. The company views a firm commitment to the principles of social and environmental responsibility as a prerequisite for its sustainable and effective development.

Media Contact
Company Name: Halmahera Resources
Contact Person: Peter Thohir
Email: Send Email
Address:Jl. Jend. Sudirman No.kav. 5 – 6, RT.10/RW.11, Karet Tengsin, Tanahabang
City: Kota Jakarta Pusat
State: Daerah Khusus Ibukota Jakarta
Country: Indonesia
Website: https://halmaheraresources.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Halmahera Resources Works on Building a Stronger Line of Security

“Errare Humanum Est” the new Celtic song by Andrea Seki and Kristen Nikolas

“Errare Humanum Est” (Atlanteans Resonances Records) is poised for release on December 21, 2023, coinciding with the winter solstice—a song celebrating the beauty of flaws and inviting souls to find solace in the timeless melodies woven by Andrea Seki and Kristen Nikolas.

In the heart of the Celtic realms, where melodies dance with the wind and stories are whispered by ancient stones, there exists a harmony born of souls intertwined. Andrea Seki, a harpist, composer, and author, traces his musical journey through the intricate tapestry of his experiences and collaborations that have shaped his ethereal compositions.

His odyssey began amidst the enchanting landscapes of Brittany, where the whispers of the harp led him to the National School of Brest, guided by the revered Breton bard Alan Stivell. Here, Andrea delved into the realms of Celtic and neo-Celtic harps, steeping himself in their evocative, legendary essence.

Under the tutelage of the bardic harpist Myrdhin, founder of the International Celtic Harp Encounters in Dinan, Andrea honed his craft. Over the years, he immersed himself in the musical traditions of Brittany and Ireland, exploring the Vedic music of northern India and delving into ancient and modern sounds, from folk rock to classical and the cutting-edge realms of electro and trance.

The fruits of his artistic labor are strewn across a discography that spans decades, each album a testament to his evolution as an artist. From the ethereal whispers of “Fairylands” to the enchanting melodies of “A Journey to the Other Land,” Andrea’s compositions echo with a profound connection to nature, history, and the mythical.

But his story intertwines with another luminary of the Celtic musical landscape—Kristen Nikolas. A singer, songwriter, and seeker of ancient Celtic wisdom, Kristen’s path converged with Andrea’s in 1996. United by their reverence for ancient Celtic civilizations and maritime lore, their collaboration bore fruit in the stirring strains of “Son Atlantel” and continued to flourish through the resonating notes of “Errare Humanum Est.”

Kristen’s lyrical prose weaves tales inspired by life’s tapestry, drawn from encounters and the essence of the human experience. He shares his poetic process, a communion with nature, where words dance freely guided by the rhythm of the earth and sky. His writings, timeless and metaphoric, echo sentiments of unity amidst diversity—a testament to the beauty of our differences.

Their latest endeavor, “Errare Humanum Est,” (Atlanteans Resonances Records) melds Andrea’s evocative harp compositions with Kristen’s poignant verses. This melodic narrative, a synthesis of their artistic spirits, speaks of the human condition—its faults, its journey, and its intrinsic connection to the universal essence.

In this musical alchemy, they’ve beckoned a troupe of talented musicians, forging a new musical venture known as “C’hez An Avel Project” or “The Breath of the Wind.” With each member a virtuoso in their own right, the ensemble embodies a fusion of Breton and Tuscia influences, adding a touch of southern Italian melodies and chants by Biagio Accardi to the symphony.

The journey of their collaboration transcends geographical boundaries, echoing the mysticism of ancient lands—the Bretagne embracing Andrea for almost three decades, echoing the sacredness of Tuscia, a cradle of Etruscan and maritime cultures.

Patrice Marzin, an esteemed figure in Breton and Celtic music, echoed the magic woven by Andrea and Kristen, their harmonies a testament to a profound musical and human connection.

Their composition, a fusion of ancient echoes and contemporary resonance, is an invocation—an invitation for humanity to embrace its fallibilities and reconnect with its universal spirit. It is a symphony that celebrates the beauty of imperfections, urging us to dance to the rhythm of our own existence.

As they unleash this latest opus into the world, Andrea Seki and Kristen Nikolas stand as custodians of a musical heritage, weaving melodies that transcend time, beckoning souls to find solace and illumination in the symphony of life.

Errare Humanum Est (Atlanteans Resonances Records) will be released on Spotify and all digital streaming music providers around the world on December 21, 2023, the day of the winter solstice.

Credits:

Original music composed by Kristen Nikolas and Andrea Seki

Lyrics by Kristen Nikolas

Andrea Seki: Neo-Celtic harp, loops, fx, moog-bass, and backing vocals.

Kristen Nikolas: Singer and vocals

Konogan An Habask: Biniou, bombarde, uilian pipe, Low-istle

Daniele Sechi: Drums

Didier Dreo: Electric guitars Guest 

Massimiliano Gallo: Viola Guest 

Federica Faith: Choirs Guest 

Alauna: Choirs – Expression vocal fx Guest 

Biagio Accardi: Narrated voice Guest 

Maxime Bourdon: Harmonica

Franky Cosentino: Sound recording and editing

Patrice Marzin @ Seniprod Kemper Studio – Mixing and mastering

Fabrizio Mancini: Artwork cover

Artistic director: Andrea Seki

Management/promotion/communication: Karine Hermen 

Record Label: Atlanteans Resonances Records

Music publisher: Magic&Unique Music Publishing

Distribution: Magic&Unique Group LTD

Media Contact
Company Name: MAGIC&UNIQUE GROUP
Contact Person: JP DEVERA
Email: Send Email
Phone: +1 424 777 2283
City: LOS ANGELES
Country: United States
Website: www.magicandunique.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: \”Errare Humanum Est\” the new Celtic song by Andrea Seki and Kristen Nikolas

Sensorineural Hearing Loss Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Sensorion, Fennec Pharma, Sound Pharma, Decibel

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Sensorineural Hearing Loss pipeline constitutes 15+ key companies continuously working towards developing 15+ Sensorineural Hearing Loss treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Sensorineural Hearing Loss Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Sensorineural Hearing Loss Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sensorineural Hearing Loss Market.

 

Some of the key takeaways from the Sensorineural Hearing Loss Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Sensorineural Hearing Loss treatment therapies with a considerable amount of success over the years. 
  • Sensorineural Hearing Loss companies working in the treatment market are Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others, are developing therapies for the Sensorineural Hearing Loss treatment 
  • Emerging Sensorineural Hearing Loss therapies in the different phases of clinical trials are- ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others are expected to have a significant impact on the Sensorineural Hearing Loss market in the coming years.   
  • In January 2022, Sensorion reported that the Phase II AUDIBLE-S clinical trial investigating its drug candidate SENS-401 (Arazasetron) for the treatment of sudden sensorineural hearing loss (SSNHL) did not achieve its primary objective. The treatment did not demonstrate a significant improvement of 15 decibels (dB) in pure tone audiometry (PTA) within the affected ear compared to the placebo after four weeks of treatment, which was the primary endpoint.

 

Sensorineural Hearing Loss Overview

Sensorineural hearing loss (SNHL) occurs due to damage to inner ear structures or the auditory nerve. It accounts for over 90 percent of hearing impairment in adults. Typical causes of SNHL include prolonged exposure to loud noises, genetic predisposition, or the natural aging process.

 

Get a Free Sample PDF Report to know more about Sensorineural Hearing Loss Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/sensorineural-hearing-loss-pipeline-insight

 

Emerging Sensorineural Hearing Loss Drugs Under Different Phases of Clinical Development Include:

  • Cochlear Hair Cell Regeneration: Decibel Therapeutics
  • HY01: Suzhou Pharmaceutical Technology Co.,Ltd
  • AC102: AudioCure Pharma GmbH
  • SENS-401: Sensorion
  • ACOU085: Acousia Therapeutics

 

Sensorineural Hearing Loss Route of Administration

Sensorineural Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Sensorineural Hearing Loss Molecule Type

Sensorineural Hearing Loss Products have been categorized under various Molecule types, such as

  • Products have been categorized under various Molecule types such as
  • Oligonucleotide
  • Peptide
  • Small molecule

 

Sensorineural Hearing Loss Pipeline Therapeutics Assessment

  • Sensorineural Hearing Loss Assessment by Product Type
  • Sensorineural Hearing Loss By Stage and Product Type
  • Sensorineural Hearing Loss Assessment by Route of Administration
  • Sensorineural Hearing Loss By Stage and Route of Administration
  • Sensorineural Hearing Loss Assessment by Molecule Type
  • Sensorineural Hearing Loss by Stage and Molecule Type

 

DelveInsight’s Sensorineural Hearing Loss Report covers around 15+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Sensorineural Hearing Loss product details are provided in the report. Download the Sensorineural Hearing Loss pipeline report to learn more about the emerging Sensorineural Hearing Loss therapies

 

Some of the key companies in the Sensorineural Hearing Loss Therapeutics Market include:

Key companies developing therapies for Sensorineural Hearing Loss are – Sensorion, Fennec Pharmaceuticals, Sound Pharmaceuticals, Decibel Therapeutics, Akouos, and others.

 

Sensorineural Hearing Loss Pipeline Analysis:

The Sensorineural Hearing Loss pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Sensorineural Hearing Loss with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sensorineural Hearing Loss Treatment.
  • Sensorineural Hearing Loss key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Sensorineural Hearing Loss Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sensorineural Hearing Loss market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Sensorineural Hearing Loss drugs and therapies

 

Sensorineural Hearing Loss Pipeline Market Drivers

  • Rise in the Incidence of Sensorineural hearing loss, rising Awareness and Initiatives about Hearing loss are some of the important factors that are fueling the Sensorineural Hearing Loss Market.

 

Sensorineural Hearing Loss Pipeline Market Barriers

  • However, high Cost of treatment, presence of Substitute Products and other factors are creating obstacles in the Sensorineural Hearing Loss Market growth.

 

Scope of Sensorineural Hearing Loss Pipeline Drug Insight    

  • Coverage: Global
  • Key Sensorineural Hearing Loss Companies: Acousia Therapeutics, Decibel Therapeutics, Suzhou Pharmaceutical Technology Co.,Ltd, AudioCure Pharma GmbH, Sensorion, and others
  • Key Sensorineural Hearing Loss Therapies: ACOU085, Cochlear Hair Cell Regeneration, HY01, AC102, SENS-401, and others
  • Sensorineural Hearing Loss Therapeutic Assessment: Sensorineural Hearing Loss current marketed and Sensorineural Hearing Loss emerging therapies
  • Sensorineural Hearing Loss Market Dynamics: Sensorineural Hearing Loss market drivers and Sensorineural Hearing Loss market barriers 

 

Request for Sample PDF Report for Sensorineural Hearing Loss Pipeline Assessment and clinical trials

 

Table of Contents

1. Sensorineural Hearing Loss Report Introduction

2. Sensorineural Hearing Loss Executive Summary

3. Sensorineural Hearing Loss Overview

4. Sensorineural Hearing Loss- Analytical Perspective In-depth Commercial Assessment

5. Sensorineural Hearing Loss Pipeline Therapeutics

6. Sensorineural Hearing Loss Late Stage Products (Phase II/III)

7. Sensorineural Hearing Loss Mid Stage Products (Phase II)

8. Sensorineural Hearing Loss Early Stage Products (Phase I)

9. Sensorineural Hearing Loss Preclinical Stage Products

10. Sensorineural Hearing Loss Therapeutics Assessment

11. Sensorineural Hearing Loss Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Sensorineural Hearing Loss Key Companies

14. Sensorineural Hearing Loss Key Products

15. Sensorineural Hearing Loss Unmet Needs

16 . Sensorineural Hearing Loss Market Drivers and Barriers

17. Sensorineural Hearing Loss Future Perspectives and Conclusion

18. Sensorineural Hearing Loss Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sensorineural Hearing Loss Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Sensorion, Fennec Pharma, Sound Pharma, Decibel

Insulin Resistance Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Exscien Corp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Insulin Resistance Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

“Insulin Resistance Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.

 

Some of the key takeaways from the Insulin Resistance Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Insulin Resistance treatment therapies with a considerable amount of success over the years. 
  • Insulin Resistance companies working in the treatment market are Tonix Pharmaceuticals, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others, are developing therapies for the Insulin Resistance treatment 
  • Emerging Insulin Resistance therapies in the different phases of clinical trials are- TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others are expected to have a significant impact on the Insulin Resistance market in the coming years.   
  • In March 2023, OrsoBio has launched a Phase 2a trial to assess the safety, tolerance, and effectiveness of TLC-3595 in individuals with Insulin Resistance. This study adopts a multicenter, double-blind, randomized approach. Participants will be randomly assigned to one of three treatment groups, receiving either one of the two doses of TLC-3595 or a matching placebo.
  • In November 2022, OrsoBio obtained exclusive global rights to an ACC2 inhibitor program from Shionogi, which encompasses the intellectual property of the primary candidate TLC-3595 (formerly S-723595). This innovative and specific ACC2 inhibitor is developed to address type 2 diabetes by enhancing fatty acid oxidation (FAO), lessening ectopic lipid buildup, and enhancing insulin sensitivity in both skeletal muscle and liver tissues.

 

Insulin Resistance Overview

Insulin Resistance is a state wherein the body’s cells exhibit reduced responsiveness to the hormone insulin. Insulin, produced by the pancreas, plays a vital role in managing blood sugar (glucose) levels and facilitating the transfer of glucose from the bloodstream into cells, where it can be utilized for energy.

 

Get a Free Sample PDF Report to know more about Insulin Resistance Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/insulin-resistance-pipeline-insight

 

Emerging Insulin Resistance Drugs Under Different Phases of Clinical Development Include:

  • TNX-1900: Tonix Pharmaceuticals
  • Steglatro: Pfizer
  • TLC-3595: OrsoBio
  • Ladarixin: Dompe Farmaceutici
  • Avandia: GlaxoSmithKline
  • Triflusal (DCI): J. Uriach and Company
  • MICARDIS® (telmisartan): Boehringer Ingelheim
  • U-500 insulin: Eli Lilly and Company
  • Vildagliptin: Novartis
  • GFT505: Genfit
  • Nateglinide: Novartis
  • Olmesartan medoxomil: Daiichi Sankyo, Inc.

 

Insulin Resistance Route of Administration

Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Intravenous
  • Subcutaneous

 

Insulin Resistance Molecule Type

Insulin Resistance Products have been categorized under various Molecule types, such as

  • Small molecule
  • Cell Therapy
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Insulin Resistance Pipeline Therapeutics Assessment

  • Insulin Resistance Assessment by Product Type
  • Insulin Resistance By Stage and Product Type
  • Insulin Resistance Assessment by Route of Administration
  • Insulin Resistance By Stage and Route of Administration
  • Insulin Resistance Assessment by Molecule Type
  • Insulin Resistance by Stage and Molecule Type

 

DelveInsight’s Insulin Resistance Report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Insulin Resistance product details are provided in the report. Download the Insulin Resistance pipeline report to learn more about the emerging Insulin Resistance therapies

 

Some of the key companies in the Insulin Resistance Therapeutics Market include:

Key companies developing therapies for Insulin Resistance are – Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, Trigemina Inc, and others.

 

Insulin Resistance Pipeline Analysis:

The Insulin Resistance pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Insulin Resistance with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Insulin Resistance Treatment.
  • Insulin Resistance key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Insulin Resistance Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Insulin Resistance market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Insulin Resistance drugs and therapies

 

Insulin Resistance Pipeline Market Drivers

  • Increasing prevalence of chronic diseases, particularly diabetes, government initiatives to motivate research in diabetes, aging population and increasing obesity prevalence in developing countries are some of the important factors that are fueling the Insulin Resistance Market.

 

Insulin Resistance Pipeline Market Barriers

  • However, less clinical information on insulin resistance has restricted the scope of drug development, limited drugs approved by the FDA are available in the market for the treatment of insulin resistance and other factors are creating obstacles in the Insulin Resistance Market growth.

 

Scope of Insulin Resistance Pipeline Drug Insight    

  • Coverage: Global
  • Key Insulin Resistance Companies: Tonix Pharmaceuticals, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others
  • Key Insulin Resistance Therapies: TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others
  • Insulin Resistance Therapeutic Assessment: Insulin Resistance current marketed and Insulin Resistance emerging therapies
  • Insulin Resistance Market Dynamics: Insulin Resistance market drivers and Insulin Resistance market barriers 

 

Request for Sample PDF Report for Insulin Resistance Pipeline Assessment and clinical trials

 

Table of Contents

1. Insulin Resistance Report Introduction

2. Insulin Resistance Executive Summary

3. Insulin Resistance Overview

4. Insulin Resistance- Analytical Perspective In-depth Commercial Assessment

5. Insulin Resistance Pipeline Therapeutics

6. Insulin Resistance Late Stage Products (Phase II/III)

7. Insulin Resistance Mid Stage Products (Phase II)

8. Insulin Resistance Early Stage Products (Phase I)

9. Insulin Resistance Preclinical Stage Products

10. Insulin Resistance Therapeutics Assessment

11. Insulin Resistance Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Insulin Resistance Key Companies

14. Insulin Resistance Key Products

15. Insulin Resistance Unmet Needs

16 . Insulin Resistance Market Drivers and Barriers

17. Insulin Resistance Future Perspectives and Conclusion

18. Insulin Resistance Analyst Views

19. Appendix

20. About DelveInsight

 

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Insulin Resistance Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Exscien Corp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics

Spectacular Success: Miss Nation Universe 2024 Crowns International Successors

In a dazzling spectacle held at the Westin Tampa Waterside Hotel on November 12th, 2024, the Miss Nation Universe Pageant celebrated the coronation of its international successors. The event showcased the rich diversity of cultures, with delegates proudly representing their heritages from the USA, Canada, the Caribbean, South America, Europe, and Africa.

Keyara Nelson

Photo Credits: Anthony Lewis

The illustrious winners of Miss Nation Universe 2024 included Keyara Nelson from Canada, capturing the coveted title. The impressive lineup also featured Myracle Brunette from the USA as Miss Teen Nation Universe 2024, Merlyn Mantilla from the USA as Ms. Nation Universe 2024, Sheena Osman from Canada as Ms. Ambassador Nation Universe, Brooke Dusoe from the USA as Mrs. Nation Universe 2024, and Jael Wambui from Kenya as Little Miss Nation Universe 2024.

Behind the scenes, the event’s glamour was complemented by the exceptional talent of makeup and hair artists, including Cateira Brown, Jeannette Gonzalez, Sofia Thomasulo, Emily Boltin, Karen Trejo, Isabela Cainas, and Rossy Bastidas. Their skillful touch enhanced the beauty of the contestants, adding an extra layer of elegance to the evening.

Myracle Brunette

Photo Credits: Anthony Lewis

To add to the excitement of this incredible event, we had music by DJ Ruben Pimentel had live performances from salsa sensation Richie Godoy and mambo maestro Gusfino.

The delegates stages of competition were panel interview, swim or athletic wear, evening gown competition and the final on stage questions. The delegates also entertained the guests in their national costumes, during the national costume parade. Judges looked for poise, confidence, grace and the ability for the contestants to represent themselves and their title.

This year’s Miss Nation Universe pageant not only celebrated beauty but also emphasized the importance of embracing diversity and cultural pride. The winners, each with their unique backgrounds, stand as ambassadors of unity and inclusivity on the international stage.

The Miss Nation Universe pageant is the international competition of the renowned Miss US Nation Pageant. A pageant known for assisting aspiring models to gain leverage in the fashion industry and reach their goals being featured on international runways, front cover magazines and more. The road to the crown tour covers various cities throughout the globe in search of the next girl to ultimately win the international crown.

As the curtains close on this unforgettable evening, the newly crowned titleholders embark on their journey as representatives of Miss Nation Universe 2024, promising to inspire and empower communities worldwide.

Photography Credits: Anthony Lewis (Instagram @ablstudios)

Media Contact
Company Name: Miss US Nation Pageants
Contact Person: Media Relations
Email: Send Email
Phone: (954) 274-5600
Country: United States
Website: www.missusnationpageants.com

RenovoRx (NASDAQ: RNXT) Elevates IP Portfolio with New Application and Advances Cancer Treatments in Phase 3 Clinical Trials

– Clinical-Stage Biopharma Company Developing Proprietary Targeted Combination Therapies for High Unmet Medical Needs in Oncology.  

– Trans-Arterial Micro-Perfusion (TAMPTM) Therapy Designed to Directly Target Tumors While Potentially Minimizing Toxicities. 

– Clinical Data Abstract to be Presented at the 2024 Society of Interventional Radiology Annual Scientific Meeting.

– Research Supports Lead Oncology Product Candidate and its Novel Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer.

– Strong Intellectual Property Portfolio with 9 Issued Patents for Proprietary Trans-Arterial Micro-Perfusion Therapy Platform and Delivery System.

– New Patent Application to Expand IP Coverage for Therapeutic Classes Across DNA/RNA Altering Modalities, Cell Therapy, and Antibody-Based Therapies.

– Welcomed Ducreux, M.D., Ph.D., Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI.

– Collaboration with Imugene validates Trans-Arterial Micro-Perfusion and Will Expand the Use of the Delivery Platform Beyond Chemotherapy to Immunotherapy.

– Therapy Platform in Phase III Clinical Trial for Pancreatic Cancer, Interim Analysis completed in March 2023 and Recommended a Continuation of the Study.

– Treatment Prespecified to Provide Primary Endpoint of a 6-Month Overall Survival Benefit. 

RenovoRx, Inc. (NASDAQ: RNXT) is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. The RNXT proprietary Trans-Arterial Micro-Perfusion (TAMPTM) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic (intravenous (IV) therapy). 

The RNXT unique approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. RNXT Phase III lead product candidate, RenovoGemTM, a novel oncology drug-device combination product, is being investigated under a US IND that is regulated by FDA 21 CFR 312 pathway. RenovoGem is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA.) RNXT is committed to transforming the lives of patients by delivering innovative solutions to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine and has not been approved for commercial sale. 

Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Research Supports RenovoRx’s Lead Oncology Product Candidate, RenovoGem™, and its Novel Therapy Platform, TAMP™, for the Treatment of Locally Advanced Pancreatic Cancer

On December 19th RNXT announced the acceptance of a clinical data abstract for the 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-28 in Salt Lake City, Utah. The abstract will highlight the RNXT lead product candidate, RenovoGem, and the proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC), a difficult-to-access, solid tumor cancer.

“We are pleased to present research supporting our TAMP therapy platform at the upcoming SIR 2024 conference, the largest professional gathering of interventional radiologists in North America,” said Shaun Bagai, CEO of RNXT. “This research adds to the continued progress of our pivotal Phase III TIGeR-PaC study in LAPC. We remain steadfast in our commitment to deliver transformative therapies to potentially extend and improve the quality of life of cancer patients.”

For more information about the conference, visit https://www.sirmeeting.org.

International Patent Application for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

On December 13th RNXT announced the Company has filed an international patent application under the Patent Cooperation Treaty (PCT) for its novel Trans-Arterial Micro-Perfusion (TAMP) therapy platform. RNXT already holds a strong intellectual property portfolio with 9 issued patents and 9 pending patents for its proprietary TAMP platform and delivery system in the US, EU, and Asia. The patent portfolio covers two main areas, mechanical and biological.

The new RNXT international patent application is filed under the Patent Cooperation Treaty on methods and apparatuses that may be used to deliver one or more therapeutic agents through the vasa vasorum (small blood vessels that supply the walls of larger arteries or veins) to a target tissue. RNXT believes that these methods and apparatuses via the TAMP therapy platform may provide a novel and important pathway for the targeted delivery of therapeutic classes across DNA/RNA-altering modalities, cell therapy, oncolytic viruses, bi-specific antibodies, and monoclonal antibodies for the treatment of a variety of clinical indications. RNXT anticipates that the patent application will be published in May of 2024.

RNXT Expands Scientific Advisory Board with Michel Ducreux, M.D., Ph.D.

On November 16th RNXT announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB). Dr. Ducreux is the Head of the Gastrointestinal Oncology Unit and Gastrointestinal Oncology Tumor Board at Gustave Roussy, Professor of Oncology at Paris-Saclay University in France, and Vice-Chair of ESMO GI.

Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud. Dr. Ducreux earned his master’s degree in biological sciences and Ph.D. in health sciences. He has held previous positions as assistant physician and professor of oncology at the Gastrointestinal Oncology Unit of Gustave Roussy and Paul Brousse Hospital in Villejuif, France. He was a Medical Affairs Director at Gustave Roussy from January 2011 to December 2019. He is the former Chair of the European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Tract Cancer Group and the former Chair of the Gastrointestinal Group of the French Federation of Anticancer Centers (FNCLCC). He is a co-editor for Gastrointestinal Oncology of the European Journal of Cancer.

Third Quarter 2023 Financial Results and Operational Highlights

On November 11th RNXT announced financial results for the third quarter ended September 30, 2023.

Key Business Highlights:

Continued to advance RNXT Phase III TIGeR-PaC clinical trial for the treatment of LAPC. The first of two interim analyses was completed in March 2023, and the Data Monitoring Committee recommended a continuation of the study. The study is prespecified to provide a primary endpoint of a 6-month OS benefit and secondary endpoints including reduced adverse events versus standard of care. Additionally, Dr. Michael J. Pishvaian, Johns Hopkins Medicine and Principal Investigator of TIGeR-PaC, presented at the Global Summit on Gastrointestinal Malignancies in Bermuda. The presentation, “Increasing Local Gemcitabine Delivery Using TAMP in the Chemotherapy Advances in Pancreatic Cancer,” highlighted the proprietary TAMP therapy platform and its design to ensure precise delivery for targeted treatment of cancer, and its potential for increased safety, tolerance, and improved efficacy.

Ripal Gandhi, FSIR, FSVM, investigator in the TIGeR-PaC study, presented, “Advances in Pancreatic Cancer: Trans-arterial Therapy on the Horizon,” at the Symposium on Clinical Interventional Oncology (CIO) on September 22-24, 2023, in Orlando, Florida. Dr. Gandhi highlighted the TAMP therapy platform as a potential targeted treatment option for patients diagnosed with locally advanced pancreatic cancer versus the standard of care. Dr. Gandhi is a member of the Miami Cancer Institute and Miami Cardiac and Vascular Institute physician team, a Clinical Professor at Florida International University Herbert Wertheim College of Medicine, and an Associate Professor at USF School of Medicine.

Collaboration with Imugene Ltd (ASX: IMU) further validates the TAMP platform and will expand the use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy.

Financial Highlights for Third Quarter ended September 30, 2023:

RNXT Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.

R&D Expenses: Research and development expenses were $1.6 million for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022. The increase was primarily due to our ongoing Phase III clinical trial cost of $0.4 million, an increase in employee and related benefits costs of $0.3 million, and general and administrative allocated costs of $0.2 million. This increase was partially offset by a decrease in costs associated with a secondary manufacturer of $0.1 million.

G&A Expenses: General and administrative expenses were $1.3 million for the third quarter ended September 30, 2023, flat compared to the same period last year. Employee and related benefits costs increased $0.3 million compared to the same quarter last year. This increase was offset by a decrease in directors’ and officers’ insurance expenses of $0.1 million, including allocation of general and administrative expenses to research and development of $0.2 million.

Net Loss: Net loss was $1.4 million for the quarter ended September 30, 2023, compared to net loss of $2.1 million for the quarter ended September 30, 2022. The decrease is primarily due to an increase in operating expenses of $0.8 million, offset by $1.5 million reported gain on the fair value of common warrants issued under our Registered Direct Offering in April 2023.

RNXT Share Structure: Shares of common stock outstanding, as of September 30, 2023, were 10,693,080.

For more information on $RNXT visit www.renovorx.com

$RXNT Beautiful Presentation: https://marketnewsreporting.com/innovative-therapy-for-targeted-treatment/ 

DISCLAIMER:

CAP/FrontPageStocks/CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CAP/FPS/CA is NOT affiliated in any manner with any company mentioned herein. CAP/FPS/CA is a news dissemination solutions provider and is NOT a registered broker/dealer/analyst/adviser, holds no investment licenses, and may NOT sell, offer to sell, or offer to buy any security. CAP/FPS/CA’s market updates, news alerts, and corporate profiles are NOT a solicitation or recommendation to buy, sell, or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details that were previously disseminated by the companies mentioned in this release or the opinion of the writer. CAP/FPS/ CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CAP/FPS/CA has been compensated $500 by a third party for the dissemination of this article.

Disclaimer/Safe Harbor:

These news releases and postings may contain forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In light of these uncertainties, the forward-looking events referred to in this release might not occur.

Media Contact
Company Name: RenovoRx, Inc.
Contact Person: Shaun Bagai, CEO
Email: Send Email
Phone: (650) 284-4433
Address:4546 El Camino Real Suite B1
City: Los Altos
State: California 94022
Country: United States
Website: https://renovorx.com/